Track Supriya Lifescience Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -3.03 %
Low
816.1
High
875.0
1 Month returns: -9.37 %
Low
816.1
High
1,043.2
1 Year returns: 15.05 %
Low
545.5
High
1,085.5
3 Year CAGR: 49.71 %
Low
233.3
High
1,085.5
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Supriya Lifescience Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Supriya Lifescience Ltd. Shareholding Pattern
Quarterly breakdown of Supriya Lifescience Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Supriya Lifescience Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Supriya Lifescience Ltd.?
The current share price of Supriya Lifescience Ltd. is ₹ 828.70 as of 17 Jul 2026.
What is the market capitalisation of Supriya Lifescience Ltd.?
The market capitalisation of Supriya Lifescience Ltd. stands at ₹ 6,669.63 Cr.
What is the PE ratio of Supriya Lifescience Ltd.?
The Price-to-Earnings (PE) ratio of Supriya Lifescience Ltd. is 31.89 as of the latest trailing twelve months data.
What is the ROE and ROCE of Supriya Lifescience Ltd.?
Supriya Lifescience Ltd. has a Return on Equity (ROE) of 19.06% and a Return on Capital Employed (ROCE) of 24.09% as per the latest financial reports.
What is the 52-week high and low of Supriya Lifescience Ltd.?
The 52-week high of Supriya Lifescience Ltd. is - and the 52-week low is -.
What is the dividend yield of Supriya Lifescience Ltd.?
The dividend yield of Supriya Lifescience Ltd. is 0.12% based on the current market price.
What is the FII and DII holding in Supriya Lifescience Ltd.?
Foreign Institutional Investors (FII) hold 5.16%, Domestic Institutional Investors (DII) hold 3.68% and retail/public investors hold 18.31% of Supriya Lifescience Ltd. shares.
What sector does Supriya Lifescience Ltd. belong to?
Supriya Lifescience Ltd. operates in the Healthcare sector.
What is the beta of Supriya Lifescience Ltd.?
The beta of Supriya Lifescience Ltd. is 0.67, indicating its price volatility relative to the broader market. Over the past 1 year, Supriya Lifescience Ltd. has delivered an absolute return of 16.59%.
What is the RSI of Supriya Lifescience Ltd.?
The 14-day Relative Strength Index (RSI) of Supriya Lifescience Ltd. is 40.81, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Supriya Lifescience Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 74.0 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
74.0 / 100
Moderate revenue growth and above median growth of industry
The company delivered moderate revenue growth of 18.86% for 12-month ended 31 Mar 2026 and the growth was 7.63 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 11.23
Value 18.86
-82.35114662
Moderate EPS growth and above median growth of industry
The company delivered moderate EPS growth of 11.25% for 12-month ended 31 Mar 2026 and the growth was 3.13 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.0 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 4 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at same valuation levels as industry median P/E
PE TTM of 31.89 indicates that the stock is expensive on a standalone basis. Premium to industry median P/E is modest at 3.27%
What is P/E Ratio?
Median: 30.88
Value 31.89
-44.893379.36
Low dividend yield
The company has a low dividend yield of 0.12%
What is Dividend yield?
Neutral
High ROE but declining trend
The company reported strong ROE of 19.06% for 12-month ended 31 Mar 2026 but ROE declined by -167 bps from 1 year ago
What is ROE (FY)?
High operating margin but declining trend
The company reported strong operating margin of 32.09% for 12-month ended 31 Mar 2026 but operating margin declined by -242 bps from 1 year ago
What is Operating profit margin?
Company's earnings are of moderate quality
Earnings quality score of 57.4 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
57.4 / 100
No red flags found!
No significant red flags found in the stock.
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
Satish Waman Wagh
Promoter
April-2023
Market Purchase (Acquisition)
3rd Apr 2023
67.63 %
₹ 190.22
13.00 k
₹ 24.73 lac
Satish Waman Wagh
Promoter
March-2023
Market Purchase (Acquisition)
31st Mar 2023
67.61 %
₹ 177.79
14.00 k
₹ 24.89 lac
Satish Waman Wagh
Promoter
March-2023
Market Purchase (Acquisition)
6th Mar 2023
67.60 %
₹ 203.69
8.00 k
₹ 16.30 lac
Satish Waman Wagh
Promoter
March-2023
Market Purchase (Acquisition)
6th Mar 2023
67.61 %
₹ 203.69
2.00 k
₹ 4.07 lac
Satish Waman Wagh
Promoter
March-2023
Market Purchase (Acquisition)
2nd Mar 2023
67.58 %
₹ 198.06
8.00 k
₹ 15.84 lac
Satish Waman Wagh
Promoter
March-2023
Market Purchase (Acquisition)
2nd Mar 2023
67.58 %
₹ 198.06
2.00 k
₹ 3.96 lac
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Holdings and Presence
Indices and prominent investors with a stake in this stock.
History of Supriya Lifescience Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 1/share
Record date: 5th Sep 2025Ex-date: 4th Sep 2025
Announced on: 27th May 2025
Dividend₹ 0.80/share
Record date: 20th Sep 2024Ex-date: 20th Sep 2024
Announced on: 28th May 2024
Dividend₹ 0.60/share
Record date: 15th Sep 2023Ex-date: 15th Sep 2023
Announced on: 26th May 2023
Dividend₹ 0.60/share
Record date: 2nd Sep 2022Ex-date: 1st Sep 2022
Announced on: 20th May 2022
Company Profile
Overview of Supriya Lifescience Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Companys product portfolio consists of approximately 38 API products that offer remedies in therapeutic segments, such as antihistamines, analgesics, vitamins, anesthetics and anti-asthmatics, among others. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulfate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others. The Company has manufacturing facilities located in Maharashtra.
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categor...